NASDAQ:TXG 10x Genomics (TXG) Stock Price, News & Analysis $8.31 +0.29 (+3.62%) As of 04/24/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About 10x Genomics Stock (NASDAQ:TXG) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get 10x Genomics alerts:Sign Up Key Stats Today's Range$7.86▼$8.3250-Day Range$7.14▼$12.1052-Week Range$6.78▼$29.37Volume5.77 million shsAverage Volume2.25 million shsMarket Capitalization$1.02 billionP/E RatioN/ADividend YieldN/APrice Target$19.79Consensus RatingHold Company Overview10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.Read More… 10x Genomics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks92nd Percentile Overall ScoreTXG MarketRank™: 10x Genomics scored higher than 92% of companies evaluated by MarketBeat, and ranked 60th out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus Rating10x Genomics has received a consensus rating of Hold. The company's average rating score is 2.35, and is based on 7 buy ratings, 9 hold ratings, and 1 sell rating.Amount of Analyst Coverage10x Genomics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about 10x Genomics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for 10x Genomics are expected to grow in the coming year, from ($1.43) to ($1.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of 10x Genomics is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of 10x Genomics is -5.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share Ratio10x Genomics has a P/B Ratio of 1.43. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about 10x Genomics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted11.07% of the float of 10x Genomics has been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in 10x Genomics has recently decreased by 0.17%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend Yield10x Genomics does not currently pay a dividend.Dividend Growth10x Genomics does not have a long track record of dividend growth. Sustainability and ESG4.8 / 5Environmental Score-0.73 Percentage of Shares Shorted11.07% of the float of 10x Genomics has been sold short.Short Interest Ratio / Days to Cover10x Genomics has a short interest ratio ("days to cover") of 4.1.Change versus previous monthShort interest in 10x Genomics has recently decreased by 0.17%, indicating that investor sentiment is improving. News and Social Media3.1 / 5News Sentiment1.60 News Sentiment10x Genomics has a news sentiment score of 1.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.72 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for 10x Genomics this week, compared to 6 articles on an average week.MarketBeat Follows3 people have added 10x Genomics to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, 10x Genomics insiders have bought 316.48% more of their company's stock than they have sold. Specifically, they have bought $445,600.00 in company stock and sold $106,992.00 in company stock.Percentage Held by Insiders10.03% of the stock of 10x Genomics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions84.68% of the stock of 10x Genomics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about 10x Genomics' insider trading history. Receive TXG Stock News and Ratings via Email Sign-up to receive the latest news and ratings for 10x Genomics and its competitors with MarketBeat's FREE daily newsletter. Email Address TXG Stock News Headlines10x Genomics price target lowered to $12 from $16 at BofAApril 14, 2025 | markets.businessinsider.comCathie Wood’s ARK Investment buys 191.5K shares of 10x Genomics todayApril 11, 2025 | markets.businessinsider.comCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess. The news is screaming fear. But while most traders watch their portfolios tank…April 25, 2025 | Crypto Swap Profits (Ad)Barclays Reaffirms Their Buy Rating on 10x Genomics (TXG)April 10, 2025 | markets.businessinsider.com10x Genomics price target lowered to $12 from $15 at BarclaysApril 10, 2025 | markets.businessinsider.comQ4 Earnings Outperformers: 10x Genomics (NASDAQ:TXG) And The Rest Of The Life Sciences Tools & Services StocksApril 9, 2025 | msn.comVizgen Announces End of Litigation with 10x Genomics and Harvard UniversityApril 3, 2025 | businesswire.comWe Think 10x Genomics (NASDAQ:TXG) Can Easily Afford To Drive Business GrowthMarch 27, 2025 | finance.yahoo.comSee More Headlines TXG Stock Analysis - Frequently Asked Questions How have TXG shares performed this year? 10x Genomics' stock was trading at $14.36 at the beginning of the year. Since then, TXG stock has decreased by 42.1% and is now trading at $8.31. View the best growth stocks for 2025 here. How were 10x Genomics' earnings last quarter? 10x Genomics, Inc. (NASDAQ:TXG) posted its earnings results on Wednesday, February, 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.32) by $0.08. 10x Genomics had a negative trailing twelve-month return on equity of 25.40% and a negative net margin of 29.90%. Read the conference call transcript. When did 10x Genomics IPO? 10x Genomics (TXG) raised $297 million in an initial public offering on Thursday, September 12th 2019. The company issued 9,000,000 shares at a price of $31.00-$35.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch served as the underwriters for the IPO and Cowen was co-manager. Who are 10x Genomics' major shareholders? 10x Genomics' top institutional shareholders include Assenagon Asset Management S.A. (1.42%), Rhumbline Advisers (0.10%), SG Americas Securities LLC (0.07%) and Avanza Fonder AB (0.05%). Insiders that own company stock include Serge Saxonov, Benjamin J Hindson, John R Stuelpnagel, Mathai Mammen, Justin J Mcanear, James Wilbur and Alan Mateo. View institutional ownership trends. How do I buy shares of 10x Genomics? Shares of TXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of 10x Genomics own? Based on aggregate information from My MarketBeat watchlists, some other companies that 10x Genomics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), PayPal (PYPL), Advanced Micro Devices (AMD) and CrowdStrike (CRWD). Company Calendar Last Earnings2/12/2025Today4/24/2025Next Earnings (Estimated)4/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Analytical instruments Sub-IndustryMeasuring And Control Equipment Current SymbolNASDAQ:TXG CIK1770787 Webwww.10xgenomics.com Phone925-401-7300FaxN/AEmployees1,240Year FoundedN/APrice Target and Rating Average Stock Price Target$19.79 High Stock Price Target$32.00 Low Stock Price Target$12.00 Potential Upside/Downside+138.1%Consensus RatingHold Rating Score (0-4)2.35 Research Coverage17 Analysts Profitability EPS (Most Recent Fiscal Year)($1.52) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-182,630,000.00 Net Margins-29.90% Pretax Margin-29.09% Return on Equity-25.40% Return on Assets-19.69% Debt Debt-to-Equity RatioN/A Current Ratio4.97 Quick Ratio4.26 Sales & Book Value Annual Sales$610.79 million Price / Sales1.66 Cash FlowN/A Price / Cash FlowN/A Book Value$5.81 per share Price / Book1.43Miscellaneous Outstanding Shares122,302,000Free Float108,912,000Market Cap$1.02 billion OptionableOptionable Beta2.01 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:TXG) was last updated on 4/25/2025 by MarketBeat.com Staff From Our PartnersElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowMy friends Joel and Adam have a simple motto: "For us, it's always a bull market." That’s because their 92%...Crypto Swap Profits | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding 10x Genomics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share 10x Genomics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.